A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

NCT02005315 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

DRUG: Vantictumab
DRUG: Nab-Paclitaxel
DRUG: Gemcitabine

Sponsor

OncoMed Pharmaceuticals, Inc.